source
- Intellia reports positive Phase 3 readout for CRISPR gene-editing therapy in hereditary angioedemaIntellia Therapeutics announced that its CRISPR-based therapy achieved a successful readout in a Phase 3 trial for hereditary angioedema, a rare condition marked by sudden, potentially dangerous sw…
- Eli Lilly to pay up to $2.3B for Ajax's JAK inhibitor in cancer dealEli Lilly announced a new agreement with Ajax Therapeutics to acquire rights to a JAK inhibitor called Kyle LaHucik for cancer treatment. The transaction could be worth up to $2.3 billion, reflect…